KRAS and lung carcinoma: Interestingly, the IC50 of 7T_PDO treated with adagrasib was significantly higher than that of KRAS p.G12C-mutant lung cancer cell lines, at 39.21 μM vs. 0.8954 μM, respectively (Fig. S4G).